Resistance mechanisms and combination strategies for abemaciclib with endocrine therapy

Abstract

Resistance to abemaciclib combined with endocrine therapy involves multiple molecular pathways that differ from resistance to other CDK4/6 inhibitors. Abemaciclib-resistant cells specifically upregulate oxidative phosphorylation and reactive oxygen species pathways, while palbociclib-resistant cells upregulate G2/M pathways, EMT, IL6/STAT3, and cancer stem cell pathways. Additional resistance mechanisms include Pak1 pathway hyper-activation, EGFR/HER2/AKT signaling hyper-activation, increased CDK6 expression, alterations in Rb pathway components, and PIK3CA/ESR1 mutations. Cell cycle regulatory changes include increased CDK4-p21 interaction in palbociclib-resistant cells and differential regulation of E2F, FOXM1, and cyclin proteins between resistance types.

Sequential treatment with abemaciclib following palbociclib resistance demonstrates clinical benefit, with overall survival of 42.7 months versus 17.3 months for non-sequential therapy and median PFS of 6.3 versus 4.0 months. This directional benefit—effective when switching from palbociclib to abemaciclib but not vice versa—reflects inhibitor-specific resistance mechanisms rather than class-wide resistance. Concurrent abemaciclib plus fulvestrant shows robust efficacy in treatment-naive settings, with meta-analytic hazard ratios of 0.53 for PFS and 0.76 for OS, and benefits regardless of PIK3CA or ESR1 mutation status. In established resistance contexts, triple combinations targeting specific resistance pathways (Pak1 inhibitors, EGFR/HER2 inhibitors) restore sensitivity. Tumors with G2/M pathway enrichment appear more likely to respond to abemaciclib after palbociclib resistance, while those with OXPHOS enrichment may require alternative approaches.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Screening

We screened in sources based on their abstracts that met these criteria:

• Hormone Receptor Status: Does this study involve patients with hormone receptor-positive (HR+) breast cancer?
• Abemaciclib Combination Therapy: Does this study investigate abemaciclib in combination with endocrine therapy (aromatase inhibitors, selective estrogen receptor modulators, or selective estrogen receptor degraders)?
• Research Focus: Does this study report on resistance mechanisms to abemaciclib and/or endocrine therapy OR evaluate combination strategies, sequencing, or dosing regimens of abemaciclib with endocrine agents?
• Relevant Outcomes: Does this study report relevant outcomes including progression-free survival, overall survival, response rates, biomarkers of resistance, or mechanistic endpoints?
• Study Design: Is this study a randomized controlled trial, cohort study, case-control study, case series, systematic review, meta-analysis, or preclinical study investigating resistance mechanisms or combination effects?
• Abemaciclib Data: Does this study include abemaciclib data (rather than focusing exclusively on other CDK4/6 inhibitors like palbociclib or ribociclib without any abemaciclib data)?
• Hormone Receptor Population: Does this study NOT focus exclusively on hormone receptor-negative breast cancer populations?
• Breast Cancer Indication: Does this study investigate abemaciclib for breast cancer (rather than other cancer indications)?

Results

Characteristics of Included Studies

• Study: S. Tolaney et al., 2022

  • Full text retrieved: No
  • Study type: Phase 3 clinical trial
  • Resistance background: Patients progressed on ET
  • Combination tested: Abemaciclib + fulvestrant, concurrent
  • Prior CDK4/6i exposure: None mentioned

• Study: S. Belli et al., 2023

  • Full text retrieved: Yes
  • Study type: Preclinical cell lines (T47D, MCF7) and xenografts
  • Resistance background: Acquired resistance (6 months)
  • Combination tested: Abemaciclib + fulvestrant, concurrent
  • Prior CDK4/6i exposure: None

• Study: Z. Qureshi et al., 2024

  • Full text retrieved: No
  • Study type: Meta-analysis of 22 studies, 14,010 patients
  • Resistance background: Not specified
  • Combination tested: Abemaciclib + fulvestrant or NSAI
  • Prior CDK4/6i exposure: Not specified

• Study: Elisabet Zapatero-Solana et al., 2022

  • Full text retrieved: No
  • Study type: Preclinical cell lines
  • Resistance background: Acquired resistance (120-144h)
  • Combination tested: Abemaciclib + fulvestrant or tamoxifen, sequential
  • Prior CDK4/6i exposure: Palbociclib or abemaciclib

• Additional studies revealed similar patterns with focus on concurrent and sequential combinations.

Molecular and Cellular Mechanisms of Resistance

Pathway Alterations

Multiple resistance pathways were identified across studies. Pak1 pathway hyper-activation emerged as a key mechanism, with resistant cells showing increased Pak1 expression and phosphorylation levels. MAPK and epithelial-to-mesenchymal transition pathways were commonly upregulated in resistant cells.

Cell Cycle Regulatory Changes

Cell cycle-related proteins showed complex alterations. CDK6 levels increased in abemaciclib-resistant cells compared to palbociclib-resistant cells.

Proliferation and Apoptosis Markers

Key biomarkers distinguished resistant phenotypes. Geminin-positive cells served as markers of S/G2/M cell cycle accumulation in resistant populations.

Combination Strategy Effectiveness

Sequential CDK4/6 Inhibitor Treatment

Sequential treatment with palbociclib followed by abemaciclib demonstrated effectiveness across multiple models.

Concurrent Abemaciclib Plus Endocrine Therapy

Concurrent combinations demonstrated synergy and improved outcomes.

Dosing Considerations

Clinically relevant concentrations were emphasized in preclinical studies.

Synthesis

Mechanisms Explaining Sequential CDK4/6 Inhibitor Benefit

The differential effectiveness of abemaciclib following palbociclib resistance reflects distinct molecular alterations induced by each inhibitor.

Context-Dependent Effectiveness Across Models

The effectiveness of abemaciclib combinations varies systematically across experimental contexts, with robust benefits in treatment-naive settings and diminished effectiveness in acquired resistance models.

Biomarker-Guided Treatment Selection

The heterogeneity in pathway activation across resistance models suggests opportunities for biomarker-guided sequential therapy.